Androgen metabolism and doping tests

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-002655-16-SE

Enrollment

Unknown

Registered

2008-02-06

Start date

2008-03-31

Completion date

Unknown

Last updated

2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers will be studied regarding androgen metabolism and doping tests.

Interventions

Trade Name: Testoviron depot Pharmaceutical Form: Injection INN or Proposed INN: testosterone Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 180- Tr

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy and normal laboratory test results 18-50 years of age Signed informed consent Meeting the "right" genotype Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Disease or abnormal laboratory test results NSAID use Member of a Sport Federation Malignancy within the last 5 years

Design outcomes

Primary

Measure	Time frame
Main Objective: Is it possible to improve doping tests employed today;Secondary Objective: Is it possible to improve the T/E test by using differentiated cut-off values for different genotypes? Will a combined genetic test and urine analysis improve the detection rate for nandrolone? Is it possible that NSAIDs and analgesic may mask abuse of testosterone by alteration of its disposition? To study interindividual variation in Nandrolone disposition;Primary end point(s): Genetic variability in androgen disposition - implications in doping;Timepoint(s) of evaluation of this end point: within six months after injection	—

Measure

Time frame

Main Objective: Is it possible to improve doping tests employed today;Secondary Objective: Is it possible to improve the T/E test by using differentiated cut-off values for different genotypes? Will a combined genetic test and urine analysis improve the detection rate for nandrolone? Is it possible that NSAIDs and analgesic may mask abuse of testosterone by alteration of its disposition? To study interindividual variation in Nandrolone disposition;Primary end point(s): Genetic variability in androgen disposition - implications in doping;Timepoint(s) of evaluation of this end point: within six months after injection

—

Secondary

Measure	Time frame
Secondary end point(s): genetic variations in kinetics;Timepoint(s) of evaluation of this end point: within six months after injection	—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026